Physician profile
Elizabeth A Nardacci
NPI 1356330351
$18,013.03
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $7,331 · 2023: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,853.15 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $801.23 | 2021-2022 | |
| Dexcom, INC. | $627.92 | 2021-2022 | |
| Novo Nordisk INC | $607.39 | 2021-2022 | |
| Lilly USA, LLC | $535.62 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.36 | 2021-2022 | |
| Insulet Corporation | $468.05 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $420.06 | 2021-2022 | |
| Amgen INC. | $298.63 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $273.02 | 2021-2022 | |
| Abbott Laboratories | $233.02 | 2021-2023 | Freestyle Libre 3 |
| Antares Pharma, INC. | $220.04 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $164.91 | 2021-2022 | |
| Horizon Therapeutics Plc | $148.82 | 2021 | |
| Abbvie INC. | $122.41 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $106.94 | 2021 | |
| Corcept Therapeutics | $100.49 | 2021-2022 | |
| Mannkind Corporation | $100.49 | 2023 | Afrezza |
| Beta Bionics, INC. | $53.77 | 2023 | Ilet Bionic Pancreas |
| Eusa Pharma (US) LLC | $52.06 | 2022 | |
| Recordati_rare_diseases_inc. | $52.06 | 2022 | |
| Merck Sharp & Dohme LLC | $49.96 | 2021-2022 | |
| Ibsa Pharma INC. | $44.04 | 2021-2022 | |
| Intuity Medical INC | $38.97 | 2022 | |
| Tandem Diabetes Care, INC. | $30.50 | 2021-2022 | |
| Rhythm Pharmaceuticals, INC. | $24.95 | 2022 | |
| Currax Pharmaceuticals LLC | $24.72 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.09 | 2022 | |
| Becton, Dickinson and Company | $17.98 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.34 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.26 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.08 | 2021 | |
| Radius Health, INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Nardacci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.